Literature DB >> 33472456

Silencing long non-coding RNA HNF1A-AS1 inhibits growth and resistance to TAM of breast cancer cells via the microRNA-363/SERTAD3 axis.

Ying Li1, Ling Liu1, Yidong Lv2, Yanwu Zhang2, Linlin Zhang3, Haiyang Yu3, Weifang Tian1, Zhan Zhang4, Shihong Cui4.   

Abstract

Long non-coding RNAs (lncRNAs) can exert effects on drug resistance of cancer cells. This study investigated the role of lncRNA HNF1A-antisense 1 (HNF1A-AS1) in growth and Tamoxifen (TAM) sensitivity of breast cancer (BC) cells. HNF1A-AS1 expression was promoted in BC cells and tissues. BC cells with HNF1A-AS1 silencing were constructed to detect cell proliferation. TAM resistant cell line with HNF1A-AS1 silencing and parent cell line with overexpressed HNF1A-AS1 were constructed to measure drug resistance. Silencing HNF1A-AS1 reduced proliferation and TAM resistance of BC cells. The downstream microRNAs (miRs) of HNF1A-AS1 and its targets were figured out and their functions in TAM resistance of BC cells were identified. HNF1A-AS1 sponged miR-363 to promote SERTAD3 expression. Downregulation of miR-363 or upregulation of SERTAD3 stimulated TAM resistance of BC cells. The findings in vitro were reproduced in in vivo experiments. It could be concluded that silencing HNF1A-AS1 inhibited growth and drug resistance to TAM of BC cells through the miR-363/SERTAD3 axis and the inactivation of the TGF-β/Smad pathway.

Entities:  

Keywords:  Breast cancer; LncRNA HNF1A-antisense 1; SERTAD3; TGF-β/Smad pathway; ceRNA; miR-363; tamoxifen

Mesh:

Substances:

Year:  2021        PMID: 33472456     DOI: 10.1080/1061186X.2021.1878362

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  2 in total

Review 1.  Regulatory mechanisms and potential medical applications of HNF1A-AS1 in cancers.

Authors:  Yang Zhang; Jiang Shi; Junfang Luo; Cong Liu; Lixu Zhu
Journal:  Am J Transl Res       Date:  2022-06-15       Impact factor: 3.940

2.  Long non-coding RNA FOXD3 antisense RNA 1 augments anti-estrogen resistance in breast cancer cells through the microRNA-363/ trefoil factor 1/ phosphatidylinositol 3-kinase/protein kinase B axis.

Authors:  Lili Ren; Huanhuan Zhou; Lei Lei; Yongjun Zhang; Hu Cai; Xiaojia Wang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.